DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Myocardial Protection of Exenatide in AMI

Information source: Kyunghee University Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Myocardial Infarction

Intervention: exenatide BYETTA® (Amylin-Lilly) (Drug); Saline (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Kyunghee University Medical Center

Official(s) and/or principal investigator(s):
Weon Kim, MD, PhD, Principal Investigator, Affiliation: Division of Cardiology, Department of Internal Medicine, Kyung Hee University Hospital


Experimental evidence suggests exenatide, a glucagon-like peptide 1 receptor analogue, has significant cardiovascular protective effects in various conditions. The investigators examined whether conventional use of exenatide at the time of primary percutaneous coronary intervention would reduce the infarct size in patients with ST-segment elevation myocardial infarction (STEMI).

Clinical Details

Official title: Cardioprotective Effects of Exenatide in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention ; Results of Exenatide Myocardial Protection In REvascularization (EMPIRE) Study

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: Infarct size

Secondary outcome:

Number of Participants with Adverse Events

LV function

Clinical outcomes

Detailed description: In this proof-of-concept trial, we assessed the effects of acute-phase adjunctive exenatide therapy in patients with STEMI. Infarct size after STEMI was evaluated by both cardiac magnetic resonance image and cardiac biomarkers compared with standard treatment. LV function was assessed by conventional and speckle tracking echocardiography. During 6-month follow up, the safety/tolerability of exenatide and clinical outcomes were also assessed.


Minimum age: 20 Years. Maximum age: 79 Years. Gender(s): Both.


Inclusion Criteria:

- age between 20 and 79 years

- patients presenting with first ST-segment elevation myocardial infarction

- Thrombolysis in Myocardial Infarction [TIMI] flow grade 0)

Exclusion Criteria:

- cardiac arrest

- ventricular fibrillation

- cardiogenic shock

- hemodynamic instability

- suspicious stent thrombosis

- left bundle branch block

- previous acute myocardial infarction

- previous coronary artery bypass operation

- significant valvular heart disease

- primary myocardial disease

- atrial fibrillation

- significant hepatic or renal dysfunction, hypoglycaemia,

- diabetic ketoacidosis

- active infection or chronic inflammatory disease

- malignancy

- women who were pregnant or who were of childbearing age

Locations and Contacts

Kyung Hee University Hospital, Seoul 130-872, Korea, Republic of
Additional Information

Related publications:

Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009 Feb 10;53(6):501-10. doi: 10.1016/j.jacc.2008.10.033.

Starting date: September 2009
Last updated: April 18, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017